Cargando…

Correction to: Decision Analysis: Omadacycline Relative to Moxifoxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difcile Infection

Detalles Bibliográficos
Autores principales:	Lodise, Thomas P., Mistry, Rohit, Young, Kate, LaPensee, Kenneth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8195748/ https://www.ncbi.nlm.nih.gov/pubmed/33909278 http://dx.doi.org/10.1007/s40261-021-01039-0

Ejemplares similares

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

1462. Hospital Admission Patterns in Adult Patients with Community-Acquired Bacterial Pneumonia Who Received Ceftriaxone and a Macrolide by Pneumonia Severity Index Score
por: Lodise, Thomas, et al.
Publicado: (2018)

Hospital Admission Patterns in Adult Patients with Community-Acquired Pneumonia Who Received Ceftriaxone and a Macrolide by Disease Severity across United States Hospitals
por: Lodise, Thomas P., et al.
Publicado: (2020)

Health-Related Quality of Life as Measured by the 36-Item Short Form Survey Among Adults With Acute Bacterial Skin and Skin Structure Infections who Received Either Omadacycline or Linezolid in a Phase 3 Double-Blind, Double-Dummy Clinical Trial
por: Chitra, Surya, et al.
Publicado: (2021)

Potential Cost Savings Associated with Targeted Substitution of Current Guideline-Concordant Inpatient Agents with Omadacycline for the Treatment of Adult Hospitalized Patients with Community-Acquired Bacterial Pneumonia at High Risk for Clostridioides difficile Infections: Results of Healthcare-Decision Analytic Model from the United States Hospital Perspective
por: Lodise, Thomas, et al.
Publicado: (2021)

Analysis of a Prescription Drug Prior Authorization Program in a Medicaid Health Maintenance Organization
por: LaPensee, Kenneth
Publicado: (2003)

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
por: Trang, M., et al.
Publicado: (2022)

Omadacycline Oral Dosing and Pharmacokinetics in Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
por: Leviton, Ira M., et al.
Publicado: (2022)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

661. In vitro Activity of Omadacycline and Comparator Antibiotics against Clostridioides difficile
por: Skinner, Andrew M, et al.
Publicado: (2022)

Omadacycline and Clostridioides difficile: A Systematic Review of Preclinical and Clinical Evidence
por: Garey, Kevin W., et al.
Publicado: (2022)

1492. Targeted Substitution of Omadacycline in Place of Standard of Care for CABP Treatment is Associated with a Risk Reduction of Clostridioides difficile Infection and Financial Cost Savings in the Acute Care Setting
por: Rodriguez, Mauricio, et al.
Publicado: (2020)

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study
por: Ramirez, Julio, et al.
Publicado: (2021)

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial
por: Rodriguez, George D., et al.
Publicado: (2023)

In Vitro Activity of Omadacycline, a New Tetracycline Analog, and Comparators against Clostridioides difficile
por: Begum, Khurshida, et al.
Publicado: (2020)

1037. Efficacy of Germinants and Omadacycline for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah, et al.
Publicado: (2021)

110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2019)

In Vitro Activity of Omadacycline and Five Comparators against Contemporary Ribotypes of Clostridioides difficile in Stockholm, Sweden
por: Camporeale, Angela, et al.
Publicado: (2021)

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

277. A Functional OMICs Evaluation of Omadacycline to Understand Anti-Clostridioides difficile Protective Effects
por: Jo, Jinhee, et al.
Publicado: (2023)

Correction to: Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
Publicado: (2023)

Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae
por: Bhavnani, Sujata M., et al.
Publicado: (2023)

Omadacycline for Acute Bacterial Skin and Skin Structure Infections
por: Abrahamian, Fredrick M, et al.
Publicado: (2019)

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
por: Bidell, Monique R., et al.
Publicado: (2021)

Correction to: The Unyvero Hospital-Acquired pneumonia panel for diagnosis of secondary bacterial pneumonia in COVID-19 patients
por: Tellapragada, Chaitanya, et al.
Publicado: (2021)

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2021)

Case Report: Omadacycline in the treatment of macrolide-unresponsive Mycoplasma pneumoniae pneumonia in an adolescent patient
por: Xu, Limin, et al.
Publicado: (2023)

The Role of Delafloxacin in Patients with Community-Acquired Bacterial Pneumonia in the Outpatient Setting: A Budget Impact Model
por: Lodise, Thomas P., et al.
Publicado: (2020)

Correction to: Community-Acquired Bacterial Pneumonia—Changing Epidemiology, Resistance Patterns, and Newer Antibiotics: Spotlight on Delafloxacin
por: Sharma, Roopali, et al.
Publicado: (2021)

Deficiency of the Transcriptional Repressor B Cell Lymphoma 6 (Bcl6) Is Accompanied by Dysregulated Lipid Metabolism
por: LaPensee, Christopher R., et al.
Publicado: (2014)

Molecular Mechanisms of Stem/Progenitor Cell Maintenance in the Adrenal Cortex
por: Lerario, Antonio Marcondes, et al.
Publicado: (2017)

Omadacycline: a novel aminomethylcycline
por: Burgos, Rodrigo M, et al.
Publicado: (2019)

Omadacycline: A Modernized Tetracycline
por: Gallagher, Jason C
Publicado: (2019)

Microbiology and Preclinical Review of Omadacycline
por: Karlowsky, James A, et al.
Publicado: (2019)

Investigating the immunomodulatory activities of omadacycline
por: Bryant, Amy E, et al.
Publicado: (2022)

SUN-LB39 ATAC-Seq Reveals Dynamic Changes in Chromatin Accessibility Following PKA Activation in NCI-H295R Adrenocortical Cells
por: LaPensee, Christopher Ryan, et al.
Publicado: (2020)

Ceftaroline Fosamil for the Treatment of Community-Acquired Pneumonia: from FOCUS to CAPTURE
por: Carreno, Joseph J., et al.
Publicado: (2014)

Use of Oral Tetracyclines in the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia: A Literature Review on the Often-Overlooked Antibiotic Class
por: Bidell, Monique R., et al.
Publicado: (2020)

Bisphenol A at Low Nanomolar Doses Confers Chemoresistance in Estrogen Receptor-α–Positive and –Negative Breast Cancer Cells
por: LaPensee, Elizabeth W., et al.
Publicado: (2009)

Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
por: Rodvold, Keith A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5qun4lsf5jl03sa2336dod27lj